KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Regeneron Pharmaceuticals (REGN) over the last 12 years, with Q4 2025 value amounting to $18.6 billion.

  • Regeneron Pharmaceuticals' Treasury Shares rose 2271.58% to $18.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.6 billion, marking a year-over-year increase of 2271.58%. This contributed to the annual value of $18.6 billion for FY2025, which is 2271.58% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Treasury Shares stood at $33.7 million for Q4 2025, which was up 1950.35% from $32.7 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Treasury Shares' 5-year high stood at $33.7 million during Q4 2025, with a 5-year trough of -$17.7 million in Q2 2021.
  • For the 5-year period, Regeneron Pharmaceuticals' Treasury Shares averaged around $20.4 million, with its median value being $23.0 million (2022).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Treasury Shares soared by 54586.52% in 2021 and then soared by 1436.35% in 2024.
  • Regeneron Pharmaceuticals' Treasury Shares (Quarter) stood at $8.3 billion in 2021, then increased by 25.33% to $10.4 billion in 2022, then grew by 21.32% to $12.6 billion in 2023, then rose by 20.76% to $15.2 billion in 2024, then rose by 22.72% to $18.6 billion in 2025.
  • Its last three reported values are $18.6 billion in Q4 2025, $17.9 billion for Q3 2025, and $17.3 billion during Q2 2025.